Study to Investigate Safety and Response to 1 or 2 g Rectal Suppositories Containing 5 or 10 mg NRL001.

Phase 1

Completed

• Conditions: Fecal Incontinence
• Interventions: Drug: NRL001

• Registration Number: NCT00857467
• Lead Sponsor: Norgine

Brief Summary

This is a healthy volunteer three-way crossover study. A total of 12 subjects will receive three single administrations of 1 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), with a washout period of at least 7 days between dosings. A further 12 subjects will receive three single administrations of 2 g rectal suppositories (containing either 5 mg NRL001, 10 mg NRL001 or matching placebo), again with a 7 day washout period between dosings. The pharmacodynamic response, pharmacokinetics and safety profile will be determined.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-02
• Study First Submitted: 2009-03-05
• Study First Submitted QC: 2009-03-05
• Study First Posted: 2009-03-06
• Status Verified: 2009-12
• Primary Completion: 2009-12
• Last Update Submitted: 2009-12-21
• Last Update Posted: 2009-12-23

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 36

Inclusion Criteria

1. No previous history of ano-rectal conditions or diseases
2. No history of cardiovascular disease
3. 18 to 60 years of age
4. Males and females (pre-menopausal females of child-bearing potential must be using adequate contraceptive methods and have a negative pregnancy test before the start of the study)

Exclusion Criteria

1. Use of medication in the last 30 days with a vasodilatory activity, or use of any medication currently or within the last 30 days which the Investigator believes may affect the study participation or results
2. Use of monoamine oxidase inhibitors presently or within the last 2 weeks before study participation
3. Use of any medication in the last 30 days applied to the anus and/or via the rectum
4. Application of any unlicensed medication within the previous 3 months or participation in any other research study in the last three months which involved being paid a disturbance allowance; having an invasive procedure (e.g. venepuncture >50ml, endoscopy) or exposure to ionising radiation.
5. Regular intake of more than 21 units of alcohol per week
6. History or any evidence of cardiovascular disease including ischaemic heart disease and hypertension (defined on examination: systolic blood pressure greater than 160 mmHg or diastolic blood pressure greater than 90 mmHg; based on at least two separate readings), peripheral vascular disease or Raynaud's syndrome
7. Presence of diabetes mellitus
8. History or symptoms of thyroid diseases, including hypo- or hyperthyroidism
9. Pregnant or lactating females
10. History of any clinically relevant allergy
11. Presence of concomitant gastrointestinal diseases or disorders, such as significant abdominal symptoms and haemorrhoids but also any significant organ (e.g. renal, hepatic or cardiac) dysfunction
12. Volunteers whom the Investigator feels would not comply with the requirements of the trial
13. Volunteers who have been exposed to more than 5 mSv of ionising radiation in the last 12 months.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
2 g suppository	NRL001	Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository.
1 g suppository	NRL001	Subjects receive 5 mg NRL001, 10 mg NRL001 and placebo in a 1g rectal suppository

Primary Outcome Measures

Name	Time	Method
Change in MARP after a single dose	6 hours

Secondary Outcome Measures

Name	Time	Method
Pharmacokinetic plasma assessment to determine systemic uptake	6 hours
Adverse events	6 hours
Cardiovascular parameters; heart rate and blood pressure	6 hours

Trial Locations

Locations (1)

Department of GI Surgery, Nottingham University Hospital; 🇬🇧 Nottingham, United Kingdom